Mantle Cell Lymphoma

One expert discusses the current treatment options for patients with mantle cell lymphoma as well as the potential shift away from chemotherapy in the future.

Those with a first-degree relative diagnosed with certain blood cancers may be at an increased risk for developing the disease themselves.

A slower walking pace among older adults with blood cancer can be a sign of frailty – which could be useful to know when tailoring one’s care to increase survival and lower hospitalizations.

Breakthroughs such as CAR-T cell therapy in the treatment of mantle cell lymphoma could help patients overcome drug resistance and ultimately live longer, according to Dr. Michael Wang.

Newer treatments for MCL offer hope to patients living with the fast-growing and challenging-to-treat disease.

Mantle cell lymphoma remains incurable, despite researchers’ best efforts. However, new treatment options show promise in the relapsed/refractory setting and may improve patient outcomes if moved to the front-line, according to Dr. Reem Karmali.

An expert discusses the exciting approaches under investigation in mantle cell lymphoma and insight into where future research should focus.

Maintenance therapy with Imbruvica appeared to be a feasible option for patients with mantle cell lymphoma, according to Dr. Reem Karmali.

Treatment with lisocabtagene maraleucel, also known as liso-cel, demonstrated clinical activity and appeared tolerable among patients with relapsed/refractory mantle cell lymphoma.

While many advances have been made in the treatment landscape of MCL, the need for curative treatment options may be where future research goes.

One expert discusses the significance of newer drugs and the role they play in helping patients with relapsed or refractory disease.

A small molecule drug may help to overcome resistance to Imbruvica in patients with MCL, according to preclinical study findings from The University of Texas MD Anderson Cancer Center.

Izidore S. Lossos, M.D., discussed how questions remain on how to find the least toxic therapies that will prolong survival in both young and elderly patients with mantle cell lymphoma.

A recent clinical trial is examining the combination regimen of netupitant plus palonosetron (NEPA), with hopes that it can curb nausea and vomiting both before and after chemotherapy in patients with peripheral T-cell lymphoma, Hodgkin lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma.

Surprise! You can’t believe everything you read on the internet!

While it is an exciting time for the treatment of mantle cell lymphoma (MCL), challenges still remain, according to Andre Goy, M.D., MS.

With the evolving landscape of maintenance therapies to treat patients with lymphoma following auto-HCT, a panel consensus recommended four grade A options for physicians to utilize.

The oral blood thinner Xarelto (rivaroxaban) significantly reduced blood clots for high-risk patients with cancer being treated in the outpatient setting, according to results from the CASSINI trial.

The combination regimen demonstrated improved efficacy outcomes with a tolerable profile among patients with relapsed/refractory mantle cell lymphoma.

In patients with mantle cell lymphoma, the introduction of BTK inhibitors continues to shape the treatment landscape.

While some high-risk patients with mantle cell lymphoma may benefit from aggressive initial therapy, a recent study found that this may not be necessary for others who could benefit from more targeted therapies.

The Food and Drug Administration (FDA) has granted the investigational BTK inhibitor zanubrutinib (BGB-3111) a breakthrough therapy designation for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received at least one prior therapy, according to BeiGene, the company manufacturing the agent.

The investigational targeted drug zanubrutinib (BGB-3111) appeared to be highly active, inducing an overall response rate of 83.5 percent in patients with relapsed/refractory mantle cell lymphoma, who were treated in a single-arm, open-label, multicenter, phase 2 trial.

Measuring circulating tumor DNA in the blood of patients with advanced mantle cell lymphoma may be a viable way to predict how well they will respond to specific therapies.

Treatment with Velcade (bortezomib) following induction chemotherapy and stem cell transplantation seemed safe and effective for untreated patients with mantle cell lymphoma, encouraging further evaluation for more active, less toxic targeted agents.

A recent study looked at a new combination to determine what would happen if untreated patients eligible for transplant were given alternating cycles of Rituxan plus bendamustine and Rituxan plus cytarabine as induction therapy. The study pooled findings from two clinical trials and real-world experience.

Lawrence D. Kaplan, M.D., discusses recent updates and next steps to be taken in Hodgkin, mantle cell and follicular lymphoma.

Entospletinib monotherapy yielded limited activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.

Imbruvica (ibrutinib) is a safe treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), according to a pooled analysis of four clinical trials.

The replacement of vincristine with Velcade (bortezomib) in the R-CHOP regimen for the treatment of transplantation-ineligible patients with newly diagnosed mantle cell lymphoma improved overall survival in a final analysis of the LYM-3002 trial.